Specifically, TP53 is significantly inhibited upon miR-125b replacement therapy in TP53 mutant colon cancer cells (DLD-1) compared to control (Figure 7G), followed by an overexpression of STAT3 for the same experimental protocol (Figure 7H). This evidence concerns the gene STAT3 and malignant colon neoplasm.